Cargando…

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina

Evidence regarding long term effectiveness of enzyme replacement therapy (ERT) in Fabry disease (FD) is needed. The aim of this study was to analyze in a cohort of FD patients in Argentina, the long term effectiveness of ERT on renal, cardiac and cerebrovascular parameters. METHODS: Patients with ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabrera, Gustavo, Politei, Juan, Antongiovani, Norberto, Amartino, Hernán
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423300/ https://www.ncbi.nlm.nih.gov/pubmed/28507907 http://dx.doi.org/10.1016/j.ymgmr.2017.02.005

Ejemplares similares

The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status
por: Martins, Ana M., et al.
Publicado: (2019)

Long-Term Effect of Enzyme Replacement Therapy with Fabry Disease
por: Komori, Manabu, et al.
Publicado: (2013)

Late onset variants in Fabry disease: Results in high risk population screenings in Argentina
por: Serebrinsky, G., et al.
Publicado: (2015)

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
por: Rombach, Saskia M, et al.
Publicado: (2013)

Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement Therapy
por: Morimoto, Satoshi, et al.
Publicado: (2021)

Major Organic Involvement in Women with Fabry Disease in Argentina
por: Perretta, Fernando, et al.
Publicado: (2018)

Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America
por: Solano, MarthaL., et al.
Publicado: (2020)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina
por: Jaurretche, Sebastián, et al.
Publicado: (2017)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

Short-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with Fabry Disease
por: Choi, Jin-Ho, et al.
Publicado: (2008)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
por: Scionti, Francesca, et al.
Publicado: (2017)

Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy
por: Dutra-Clarke, Marina, et al.
Publicado: (2020)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies
por: El Dib, Regina, et al.
Publicado: (2017)

Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group
por: Concolino, D., et al.
Publicado: (2017)

Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
por: Tsukimura, Takahiro, et al.
Publicado: (2020)

Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
por: Politei, Juan, et al.
Publicado: (2021)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
por: Weidemann, F, et al.
Publicado: (2013)

Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease
por: Hamed, Alaa, et al.
Publicado: (2021)

Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued
por: Politei, Juan
Publicado: (2020)

Fabry disease and COVID-19: International expert recommendations for management based on real-world experience
por: Laney, Dawn A., et al.
Publicado: (2021)

Fabry disease and COVID-19: international expert recommendations for management based on real-world experience
por: Laney, Dawn A, et al.
Publicado: (2020)

Enzyme replacement therapy for Fabry disease: some answers but more questions
por: Alfadhel, Majid, et al.
Publicado: (2011)

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease
por: Stefaniak, James D., et al.
Publicado: (2018)

Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease
por: Deng, Mulan, et al.
Publicado: (2022)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
por: Li, Qian, et al.
Publicado: (2023)

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
por: Barba-Romero, Miguel-Ángel, et al.
Publicado: (2016)

Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
por: Kim, Il Young, et al.
Publicado: (2021)

Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease
por: Okada, Jun, et al.
Publicado: (2017)

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis
por: Alegra, Taciane, et al.
Publicado: (2012)

Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy
por: Heo, Sun Hee, et al.
Publicado: (2017)

Fabry nephropathy: 5 years of enzyme replacement therapy—a short review
por: Barbey, Frédéric, et al.
Publicado: (2008)

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy
por: Iacobucci, Ilaria, et al.
Publicado: (2023)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Fabry disease: Four case reports of meningioma and a review of the literature on other malignancies
por: Thurberg, Beth L., et al.
Publicado: (2016)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hd87uuanaj7356thmau3gpita7